Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia

To assess interscanner reproducibility of tissue iron measurements in patients with thalassemia using gradient echo T2* measurements on two different MRI scanners.

[1]  Matthew Darlison,et al.  Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.

[2]  J. Porter,et al.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia , 2000 .

[3]  A. Piga,et al.  SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.

[4]  E R McVeigh,et al.  In vivo measurement of T*2 and field inhomogeneity maps in the human heart at 1.5 T , 1998, Magnetic resonance in medicine.

[5]  D. Halperin,et al.  Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. , 1993, Chest.

[6]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.

[7]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[8]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[9]  D J Pennell,et al.  Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. , 2000, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[10]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[11]  D. Pennell,et al.  Breath-hold FLASH and FISP cardiovascular MR imaging: left ventricular volume differences and reproducibility. , 2002, Radiology.

[12]  A. Hoffbrand,et al.  High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. , 1990, Acta haematologica.

[13]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .